Dr. Andrew Lewis, Chief Scientific Officer, Featured In BioPharm International: "Why AI Fails in Drug Development and How to Build Tools That Actually Deliver Real Value"
Artificial intelligence (AI) is increasingly being applied in drug development, and regulators are addressing its use as more regulatory submissions incorporate AI. Broader conversations often focus on value: improving development timelines, reducing costs, enabling better-informed decisions, and lowering the risk of late-stage failures; however, these benefits are not guaranteed by technology alone.
AI delivers the most value when paired with deep drug development expertise and designed to operate within real-world constraints, supporting the decisions scientists already have to make and fitting within workflows they trust. This requires designing and validating tools in close partnership with domain experts.
Without grounding AI in these operational realities, implementation can become tool-driven, with progress measured by models and outputs rather than outcomes that matter in practice. This perspective reflects lessons learned while building Intrepid Labs, an AI-driven drug formulation company, and collaborating with Quotient Sciences to embed AI within an established development program.
Read the full article on BioPharm International's website here.